Zacks Research Has Bullish Forecast for GSK FY2024 Earnings

GSK plc (NYSE:GSK) – Zacks Research boosted their FY2024 earnings per share (EPS) estimates for GSK in a research report issued to clients and investors on Tuesday, November 19th. Zacks Research analyst E. Bagri now expects that the pharmaceutical company will post earnings per share of $4.12 for the year, up from their previous forecast of $4.11. The consensus estimate for GSK’s current full-year earnings is $4.03 per share. Zacks Research also issued estimates for GSK’s Q1 2026 earnings at $1.14 EPS and Q3 2026 earnings at $1.57 EPS.

GSK has been the topic of several other reports. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and lowered their price target for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Argus upgraded GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, Barclays upgraded GSK to a “hold” rating in a research report on Tuesday, August 27th. Seven investment analysts have rated the stock with a hold rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Stock Up 0.8 %

GSK stock opened at $33.96 on Friday. The firm has a market cap of $70.37 billion, a price-to-earnings ratio of 22.05, a price-to-earnings-growth ratio of 1.29 and a beta of 0.66. GSK has a 52 week low of $32.83 and a 52 week high of $45.92. The business’s 50-day moving average price is $38.09 and its 200 day moving average price is $40.37. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98.

Institutional Investors Weigh In On GSK

Several hedge funds and other institutional investors have recently made changes to their positions in GSK. Eastern Bank acquired a new stake in GSK during the third quarter worth $26,000. Sunbelt Securities Inc. grew its stake in shares of GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after buying an additional 302 shares in the last quarter. Concord Wealth Partners grew its stake in shares of GSK by 231.8% in the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after buying an additional 547 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in shares of GSK in the second quarter valued at $37,000. Finally, Fortitude Family Office LLC acquired a new stake in shares of GSK in the third quarter valued at $42,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

Insider Activity

In related news, major shareholder Plc Gsk purchased 2,791,930 shares of the business’s stock in a transaction that occurred on Friday, September 27th. The stock was purchased at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the acquisition, the insider now owns 16,775,691 shares in the company, valued at $134,205,528. This trade represents a 19.97 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 10.00% of the company’s stock.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be given a $0.3928 dividend. This represents a $1.57 annualized dividend and a dividend yield of 4.63%. The ex-dividend date is Friday, November 15th. This is an increase from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio (DPR) is 98.70%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.